PCR Spotlight: antithrombotic and anticoagulant treatment in the COVID-19 era
Interventional Cardiologists Davide Capodanno, Catania, Italy, Gilles Montalescot, Paris, France, and Dominik Angiolillo, Jacksonville, USA discuss how to manage antithrombotic therapy in patients with COVID-19 undergoing interventional procedures.
Key take-home messages:
- COVID-19 disease is a prothrombotic state
- When using antiplatelets, be well aware of drug to drug interaction
- Most COVID-19 patients will require anticoagulants and LWMH is the preferred drug
- When asymptomatic, COVID-19 patients should not be switched between anticoagulants
Speakers
This page was published on 15 May 2020.
The content of this page reflects the view of the authors/speakers at a given point in time and does not necessarily represent the view of PCR or PCRonline.